Another FDA-approved kinase inhibitor used to treat unresectable/metastatic (including CNS metastasis) HER2+ breast cancer is tucatinib, usually given in combination with trastuzumab and capecitabine. This evidence concerns the gene ERBB2 and breast carcinoma.